Pharmaceutical Firms Target KRAS Mutation with New Drugs
Pharmaceutical companies have developed new drugs targeting the KRAS mutation, a previously 'undruggable' cancer mutation. The introduction of these drugs marks a significant advancement in cancer treatment. This development comes as researchers continue to explore additional therapeutic options.
KRAS Mutation Targeting
The KRAS protein mutation has long been a challenge for cancer researchers due to its complex structure. Recent advancements have led to the development of drugs that can effectively target this mutation. Companies like Amgen and Mirati Therapeutics are at the forefront, with clinical trials showing promising results.
Clinical Trial Outcomes
Clinical trials have demonstrated significant tumor reduction in patients with KRAS mutations. Amgen's drug, Lumakras, has shown a 36% response rate in trials. Meanwhile, Mirati's adagrasib has also reported positive outcomes, with ongoing studies to confirm long-term efficacy.
KRAS Mutation Prevalence
KRAS is the most frequently mutated isoform among RAS oncogenes, accounting for approximately 85% of RAS mutations in human cancers. This high prevalence has led to intensive research efforts focused on understanding and targeting KRAS mutations.
KRAS Inhibitors Market Emergence
KRAS inhibitors have transitioned from being considered 'undruggable' to becoming a validated drug class in precision oncology. This shift marks the emergence of a new commercial market for these inhibitors, as highlighted by recent internal research from APO Research.
What's Next
Regulatory bodies are expected to review these drugs for approval in the coming months. The long-term impact on cancer treatment remains uncertain as further studies are needed.
3 sources
Pharmaceutical Firms Target KRAS Mutation with New Drugs
